QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
QQQ   419.93 (-0.82%)
AAPL   165.30 (-1.04%)
MSFT   402.41 (-0.46%)
META   489.00 (-2.55%)
GOOGL   154.77 (-0.79%)
AMZN   176.72 (-1.39%)
TSLA   150.27 (+0.23%)
NVDA   821.94 (-2.93%)
AMD   151.60 (-2.24%)
NIO   3.87 (-3.25%)
BABA   68.80 (-0.12%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   109.22 (-2.42%)
GE   151.72 (-0.80%)
CGC   7.69 (-1.79%)
DIS   112.14 (-0.26%)
AMC   3.18 (+8.90%)
PFE   25.65 (+1.02%)
PYPL   62.22 (+0.19%)
XOM   120.52 (+1.69%)
Free Trial
LON:STX

Shield Therapeutics (STX) Share Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free STX Stock Alerts
GBX 1.45
-0.03 (-1.69%)
(As of 03:39 PM ET)
Compare
Today's Range
1.42
▼
1.50
50-Day Range
1.45
▼
5.86
52-Week Range
1.42
▼
12.85
Volume
1.17 million shs
Average Volume
5.25 million shs
Market Capitalization
£11.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsHeadlines
STX stock logo

About Shield Therapeutics Stock (LON:STX)

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

STX Stock Price History

STX Stock News Headlines

April 10, 2024 | msn.com
Neutral Switzerland joins European Sky Shield defence project
April 1, 2024 | tmcnet.com
American Home Shield Offering 40% Off ShieldGold™ For Limited Time
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
March 29, 2024 | msn.com
A Real Life Invisibility Shield for Privacy in Public Places
March 11, 2024 | tmcnet.com
Seal Shield to Showcase Shyld AI, the World's First Intelligent, Autonomous, UV-C Disinfection System at HIMSS 2024
February 23, 2024 | lse.co.uk
LONDON MARKET CLOSE: FTSE 100 takes hit ahead of FOMC minutes
February 22, 2024 | morningstar.com
Shield Therapeutics PLC STX
February 13, 2024 | uk.finance.yahoo.com
Shield Therapeutics plc (STX.L)
April 19, 2024 | InvestorPlace (Ad)
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
January 24, 2024 | finance.yahoo.com
Shield Therapeutics (LON:STX) shareholders have endured a 89% loss from investing in the stock three years ago
December 28, 2023 | finance.yahoo.com
Shield Therapeutics plc (LON:STX) Is Expected To Breakeven In The Near Future
October 20, 2023 | proactiveinvestors.com
Shield Therapeutics to present at NPWH conference this month
October 12, 2023 | marketwatch.com
Shield Therapeutics CFO Hans-Peter Rudolf to Step Down
October 12, 2023 | proactiveinvestors.com
Shield Therapeutics launches executive search process as CFO steps down
October 5, 2023 | finance.yahoo.com
Shield Therapeutics "couldn't be more pleased" with Viatris collaboration
October 5, 2023 | finance.yahoo.com
Shield Therapeutics' pricing will be "key metric" - Proactive Research Analyst
October 3, 2023 | proactiveinvestors.com
Shield Therapeutics secures debt facility, retail share offer closes soon
September 30, 2023 | finance.yahoo.com
Shield Therapeutics First Half 2023 Earnings: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)
September 29, 2023 | msn.com
Shield Therapeutics hails progress in Stateside venture as losses narrow
September 28, 2023 | marketwatch.com
Shield Therapeutics Shares Fall After Discounted Equity Raise
September 5, 2023 | finance.yahoo.com
Private companies who hold 41% of Shield Therapeutics plc (LON:STX) gained 17%, institutions profited as well
July 29, 2023 | proactiveinvestors.com
Shield Therapeutics : First signs of hoped-for Accrufer Rx inflection
July 25, 2023 | finanznachrichten.de
Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
July 25, 2023 | finance.yahoo.com
Shield Therapeutics "really starting to fire on all cylinders"
July 20, 2023 | marketwatch.com
Shield Therapeutics Shares Rise as US Prescriptions for Accrufer Soar
July 20, 2023 | msn.com
Shield Therapeutics makes waves in US as iron deficiency prescriptions ramp up
July 20, 2023 | proactiveinvestors.com
Shield Therapeutics reports 173% Accrufer prescription growth
See More Headlines
Receive STX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shield Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
LON:STX
CUSIP
N/A
CIK
N/A
Web
www.shieldtherapeutics.com
Phone
+44-191-5118500
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
GBX (0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
63.22
P/E Growth
N/A
Net Income
£-48,880,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-146.62%
Return on Assets
-42.79%

Debt

Debt-to-Equity Ratio
21.30
Current Ratio
2.95
Quick Ratio
2.16

Sales & Book Value

Annual Sales
£7.40 million
Price / Sales
1.56
Cash Flow
GBX 0.23 per share
Price / Cash Flow
6.36
Book Value
GBX 4 per share
Price / Book
0.37

Miscellaneous

Outstanding Shares
782,060,000
Free Float
N/A
Market Cap
£11.54 million
Optionable
Not Optionable
Beta
0.84
7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Gregory P. Madison (Age 57)
    CEO & Executive Director
    Comp: $678k
  • Dr. Christian Schweiger M.D. (Age 58)
    Ph.D., Co-Founder & Non Executive Director
    Comp: $45k
  • Mr. Santosh Shanbhag (Age 46)
    Chief Financial Officer
  • Ms. Lucy Kate Huntington-Bailey
    General Counsel & Company Secretary
  • Ms. Suzanne Wood
    Group HR Director
  • Ms. Carol Akinola
    Head of Pharmacovigilance & Medical Information
  • Mr. Andrew Hurley (Age 55)
    Chief Commercial Officer
  • Kate Armanetti
    Senior Director of People & Culture

Key Competitors

View All Competitors

STX Stock Analysis - Frequently Asked Questions

How have STX shares performed in 2024?

Shield Therapeutics' stock was trading at GBX 6.70 at the beginning of the year. Since then, STX shares have decreased by 77.9% and is now trading at GBX 1.48.
View the best growth stocks for 2024 here.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS), Cellectis (CLLS), Geron (GERN), Concepta PLC (CPT.L) (CPT), Fresnillo (FRES), OptiBiotix Health (OPTI) and SkinBioTherapeutics (SBTX).

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:STX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
My biggest AI fear
Paradigm Press
How Biden has already won 2024
Porter & Company